Anokion

Focus: Anokion is a Swiss biotech focused on developing immune-tolerated therapeutic proteins for gastroenterology and neurology indications. The company is in early-stage development with two Phase 1 programs and no approved products or revenue.

Gastroenterology Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Anokion

AI assessmentNot Hiring

No open roles listed right now. Follow Anokion to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ANK-700

Relapsing Remitting Multiple Sclerosis

Phase 1

Clinical Trials (1)

NCT04602390Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Phase 1

Help build intelligence for Anokion

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a focused biotech with a differentiated platform in immune tolerance—a clinically validated approach with limited competition
Early-stage pipeline targeting high-unmet-need indications (multiple sclerosis, celiac disease) with potential for significant impact
Swiss location offers stable regulatory environment and strong biotech ecosystem access

Watch Out For

Pre-revenue status with no disclosed funding, cash position, or employee headcount raises questions about financial runway and sustainability
Zero active job openings and minimal pipeline depth (only 2 Phase 1 programs) suggest limited near-term growth and hiring
Early-stage risk: no marketed products, no clinical proof-of-concept beyond Phase 1, and no publications indexed suggest technology validation is incomplete

Generated by Claude from Anokion's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

KAN-101

Celiac Disease

Phase 1

Clinical Trials (2)

NCT06001177A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

Phase 2

NCT04248855Assessment of KAN-101 in Celiac Disease (ACeD)

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Gastroenterology, Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Gastroenterology

2 pipeline

Neurology

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles